1. Butler EB, Zhao Y, Munoz-Pinedo C, Lu J, Tan M. Stalling the engine of resistance:targeting cancer metabolism to overcome therapeutic resistance. Cancer Res. 2013; 73:2709–17.
2.Gewirtz, D. A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol, 1999. 57(7): p. 727–41.
3.Agudelo, D., et al., Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: structural features and biological implications. Int J Biol Macromol, 2014. 66: p. 144–50.
4.Evans-Roberts, K. and A. Maxwell, DNA Topoisomerases. EcoSal Plus, 2009. 3(2).
5.Mizutani, H., et al., Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci, 2005. 76(13): p. 1439–53.
6.Shaili, E., Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments. Sci Prog, 2014. 97(Pt 1): p. 20–40.
7.Galluzzi, L., et al., Molecular mechanisms of cisplatin resistance. Oncogene, 2012. 31(15): p. 1869–83.
8.Shen, D. W., et al., Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev, 2012. 64(3): p. 706–21.
9.Garraway, L. A. and E. S. Lander, Lessons from the cancer genome. Cell, 2013. 153(1): p. 17–37.
10.Vogelstein, B., et al., Cancer genome landscapes. Science, 2013. 339(6127): p. 1546–58.
11.Kadoch, C. and G. R. Crabtree, Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv, 2015. 1(5): p. e1500447.
12.Sturm, D., et al., Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer, 2014. 14(2): p. 92–107.
13.Flynn, E. M., et al., A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications. Structure, 2015. 23(10): p. 1801–1814.
14 Sun Sun, H., Liu, J., Zhang, J., Shen, W., Huang, H., Xu, C., Shi, Y. (2007). Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. Biochemical and Biophysical Research Communications, 358(2), 435–441.
15.Kang, J. U., et al., Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet, 2008. 182(1): p. 1–11.
16.Scotto, L., et al., Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer, 2008. 7: p. 58.
17.Cleary, S. P., et al., Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology, 2013. 58(5): p. 1693–702.
18.Barbieri, C. E., et al., Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet, 2012. 44(6): p. 685–9.
19.Crawford, T. D., et al., Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. Bioorg Med Chem Lett, 2017. 27(15): p. 3534–3541.
20.Hohmann, A. F., et al., Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. Nat Chem Biol, 2016. 12(9): p. 672–9.
21.Smyth EC, Verheij M, and Allum W, et al (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 27 v38–v49
22.Lu LL, Chen XH, Zhang G, Liu ZC, Wu N, Wang H, Qi YF, Wang HS, Cai SH, Du J. CCL21 Facilitates Chemoresistance and Cancer Stem Cell-Like Properties of Colorectal Cancer Cells through AKT/GSK–3beta/Snail Signals. Oxid Med Cell Longev. 2016; 2016:5874127.
23.Lindblad, M., et al., Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer, 2006. 94(1): p. 136–41.
24.Cronin-Fenton, D. P., et al., Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer, 2010. 46(11): p. 2067–76.
25.Inoue, H., et al., Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res, 2002. 8(11): p. 3475–9.
26.Skinner, H. G., et al., Parity, reproductive factors, and the risk of pancreatic cancer in women. Cancer Epidemiol Biomarkers Prev, 2003. 12(5): p. 433–8.
27.Yu, H., et al., Hormonal and reproductive factors and risk of esophageal cancer in Chinese postmenopausal women: a case-control study. Asian Pac J Cancer Prev, 2011. 12(8): p. 1953–6.
28.Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56:185–229.
29.Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349:859–66.
30.McClung EC, Wenham RM. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health. 2016; 8:59–75.
31.Kumar V, Palazzolo S, Bayda S, Corona G, Toffoli G, Rizzolio F. DNA Nanotechnology for Cancer Therapy. Theranostics. 2016; 6:710–25.
32.Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH, Twentyman PR. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst. 1994; 86:110–7.
33.Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer. 1994; 58:400–6.